Nuvation Bio Inc. (NUVB)

Market Cap	1.54B +98.1%
Revenue (ttm)	62.90M +699.0%
Net Income	-204.63M
EPS	-0.60
Shares Out	347.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,296,797
Open	4.260
Previous Close	4.380
Day's Range	4.250 - 4.470
52-Week Range	1.540 - 9.750
Beta	1.51
Analysts	Strong Buy
Price Target	11.38 (+157.47%)
Earnings Date	Mar 2, 2026

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 298
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Financial Performance

In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $11.38, which is an increase of 157.47% from the latest price.

Price Target

$11.38

(157.47% upside)

Analyst Consensus: Strong Buy